Loading
Cognition Therapeutics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Caggiano Anthony, was filed 20 Apr 2026.
Cognition Therapeutics Inc: what insiders have been doing
Cognition Therapeutics Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 21 October 2025 to 21 October 2026, the disclosure feed for Cognition Therapeutics Inc logged 17 filings by 8 insiders.
Not one open-market sale was filed. On the buying side, 3 insiders reported 3 purchases totalling €28k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 finance chief, 1 senior executive and 1 chief executive. The largest single trade was a purchase of €9,590 by Doyle John Brendan, published on 20 April 2026, equal to 0.010% of the market capitalisation.
In the case of 3 purchases, another manager of the company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 20 April 2026, 184 days ago. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,810 companies tracked on its exchange, the median is 19 filings; at 17 filings, this issuer sits below that mark. The full history, which starts in 2021, counts 21 purchases against no sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -23.5 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
83
Thresholds
n/a
Buy Volume
€867,183
21 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleLisa Ricciardi2 buys
Anthony Caggiano1 buy
John Brendan Doyle1 buy
Since the insiders bought
- -18.9%Entry US$1.17 · Close at T+90 US$0.95
- -18.9%Entry US$1.17 · Close at T+90 US$0.95
- -18.9%Entry US$1.17 · Close at T+90 US$0.95
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Cognition Therapeutics Inc Strong Buy (bullish), based on 3 analysts. Average price target: US$3.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.80
Analyst consensus
3 analystsStrong buy
US$3.00Target US$3.33(+316%)US$4.00
Income statement
EBITDA-US$23.2M
Net income-US$23.5M0.0% margin
Valuation
PER (forward)-3.6x
P/Book2.3x
Beta1.80
Balance sheet & cash
Market capUS$76.2M
Total debtUS$638k
Free Cash Flow-US$24.6M
Debt / Equity2%
Profitability & ownership
ROE-83.8%
ROA-78.2%
% insiders1.3%
% institutions23.8%
Last declaration on 22 June 2026
Declarations83 total
25,000 sharesCommon StockSEC:0001789490-26-000002:0
25,000 sharesCommon StockSEC:0001104659-26-076470:0
25,000 sharesCommon StockSEC:0001104659-26-076472:0
25,000 sharesCommon StockSEC:0001104659-26-076475:0
25,000 sharesCommon StockSEC:0001104659-26-076477:0
10,000 shares@ US$1.110.010% mcap18.1% of flowCommon StockSEC:0001104659-26-045499:0
Canonical exit: 15 Jul 2026 (T+90)
9,175 shares@ US$1.100.0093% mcap3.3% of flowCommon StockSEC:0001104659-26-045502:0
Canonical exit: 15 Jul 2026 (T+90)
10,000 shares@ US$1.130.010% mcap30.3% of flowCommon StockSEC:0001104659-26-045511:0
Canonical exit: 15 Jul 2026 (T+90)
5,850 shares@ US$1.122.1% of flowCommon StockSEC:0001104659-26-017070:0
4,680 shares@ US$1.128.5% of flowCommon StockSEC:0001104659-26-017063:0
1,560 shares@ US$1.124.6% of flowCommon StockSEC:0001104659-26-017068:0
800,000 shares0Common StockSEC:0001104659-26-011075:0
200,000 shares0Common StockSEC:0001104659-26-011074:0
400,000 shares0Common StockSEC:0001104659-26-011073:0
65,000 shares0Common StockSEC:0001104659-25-123722:0
30,000 shares0Common StockSEC:0001104659-25-123721:0
75,000 shares0Common StockSEC:0001104659-25-123727:0
7,729 shares@ US$0.840.7% of flowCommon StockSEC:0001104659-25-092671:0
30,000 shares0Common StockSEC:0001062993-25-013357:0
75,000 shares0Common StockSEC:0001062993-25-013356:0
65,000 shares0Common StockSEC:0001062993-25-013358:0
34,000 shares0Common StockSEC:0001062993-25-012082:0
34,000 shares0Common StockSEC:0001062993-25-012081:0
34,000 shares0Common StockSEC:0001062993-25-012078:0
34,000 shares0Common StockSEC:0001062993-25-012079:0
25 of 83 declarations
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc. (ticker: CGTX) is a United States-based biopharmaceutical company listed on the NASDAQ market in the United States. It is best described as a clinical-stage neuroscience company focused on discovering and developing small-molecule therapeutics for age-related degenerative diseases affecting the central nervous system and the retina. For French, Belgian and Swiss investors, CGTX belongs to the high-risk/high-upside biotech universe: the investment case is driven far more by clinical milestones and financing capacity than by commercial revenues.
The company was incorporated in 2007 and has spent years building a mechanistic, translational, and clinical research base in neurodegeneration. Its headquarters are in Purchase, New York, reinforcing its U.S. footprint and its positioning within the American biotechnology ecosystem. Cognition Therapeutics does not yet operate as a commercial pharmaceutical group with a mature product portfolio; rather, it is a development-stage company whose valuation depends primarily on the progress of its pipeline, the quality of its clinical data, and the strength of its scientific thesis.
Read moreShow less
Its core business is the discovery and development of therapies aimed at neurodegenerative disorders, with particular attention to conditions such as Alzheimer’s disease and other age-related CNS indications. The company’s lead program, zervimesine, is the key asset followed by the market, and most recent company updates have centered on that candidate’s development path. This makes CGTX comparable to other specialty neuroscience biotechs rather than to large-cap pharmaceutical companies with established sales and diversified franchises.
From a competitive standpoint, Cognition Therapeutics operates in a crowded and highly specialized field. Competition comes from both large pharmaceutical companies and a long list of smaller biotech peers pursuing disease-modifying therapies in neurology and ophthalmology. The company’s potential edge lies in the scientific differentiation of its small-molecule approach and its focus on mechanisms linked to neurodegeneration. At the same time, the development risk is substantial, as clinical setbacks, regulatory hurdles, and ongoing capital needs are typical in this segment.
Recent developments matter for the stock. In 2025, Cognition Therapeutics announced that it had regained compliance with Nasdaq’s minimum bid price requirement, reducing an important listing-risk overhang. Early 2026 company communications also highlighted first-quarter financial results and a business update focused on zervimesine. For investors monitoring SEC Form 4 insider transactions, these operational and market-structure developments provide useful context for assessing sentiment and near-term catalysts.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
